\
&
Contact us
\
&
Contact us
Published on | 8 months ago
Programmes Enhancing EU R&I Horizon EuropeThe Communication ‘Implementation of the European Research Area (ERA): Strengthening Europe’s Research and Innovation: The ERA’s Journey and Future Directions’ has been adopted on 22 October by the Commission.
The Communication takes stock and assesses the progress made since the previous Communication ‘A new ERA for Research and Innovation‘ (2020) in which the four key objectives are laid out:
and identifies remaining challenges which set the direction for future activities.
More information can be found in the European Commission press release, including a factsheet on the Communication and the videos ‘The #EUResearchArea over time: 2000 until today’ and ‘ERA testimonials’.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
